3.33 USD
▼-0.10-2.92%
盘后 3.40 +2.17%
2026-09-15
市值
$278.58M
市盈率
—
EPS
-1.40
股息率
—
52 周区间
1.03 – 5.55
成交量
489.64K
Beta
1.34
目标价
8.44
52W 低 1.0352W 高 5.55
价格走势
公司简介
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o...